490 results on '"Giladi, Moshe"'
Search Results
2. Chloride intracellular channel (CLIC) proteins function as fusogens
3. Complex biophysical changes and reduced neuronal firing in an SCN8A variant associated with developmental delay and epilepsy
4. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
5. TTYH family members form tetrameric complexes at the cell membrane
6. Abstract B032: Designing arrays for the mouse head to facilitate in vivo studies of Tumor Treating Fields (TTFields) treatment of glioblastoma
7. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models
8. Identification of a magnesium‐binding site at the primary allosteric calcium sensor of the sodium–calcium exchanger: Implications for physiological regulation.
9. Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance.
10. Water-Content Electrical Property Tomography (wEPT) for Mapping Brain Tissue Conductivity in the 200–1000 kHz Range: Results of an Animal Study
11. Abstract B071: Tumor Treating Fields (TTFields) together with PARP inhibitors for treatment of pancreatic cancer cells
12. Abstract B028: Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer
13. Teleological reasoning for QT prolongation caused by severe bradycardia: Correlation between QT interval and brain natriuretic peptide levels during atrioventricular block
14. Complex biophysical changes and reduced neuronal firing in anSCN8Avariant associated with developmental delay and epilepsy
15. 10269-ET-10 ARRAYS FOR DELIVERING TUMOR TREATING FIELDS (TTFIELDS) TO THE MOUSE HEAD
16. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
17. Structural dynamics of Na+ and Ca2+ interactions with full-size mammalian NCX.
18. Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro, and safety for application to COVID-19 patients in a pilot clinical study
19. 1080 Tumor Treating Fields (TTFields) application induces a pro-inflammatory phenotype in macrophages
20. MODL-13. DEVELOPMENT OF TUMOR TREATING FIELDS (TTFIELDS) ARRAYS FOR TREATMENT OF HEAD TUMORS IN MICE MODELS
21. Implications of electrical properties of cells for treatment specificity of electric/electromagnetic fields-based therapeutic approaches
22. Massive splenomegaly
23. Strabismus and mental disorders among Israeli adolescents
24. Structural basis of heterotetrameric assembly and disease mutations in the human cis-prenyltransferase complex
25. Defective cathepsin Z affects EGFR expression and causes autosomal dominant palmoplantar keratoderma
26. Abstract 4860: PI3K inhibition sensitize cancer cells to tumor treating fields (TTFields)
27. Abstract 6176: Enhancing treatment efficacy of glioblastoma cell lines by adding tumor treating fields (TTFields) to temozolomide and lomustine
28. Abstract 1738: Sensitizing cancer cell to doxorubicin by tumor treating fields (TTFields)-induced, elevated membrane permeability
29. Abstract 6182: Tumor treating fields (TTFields) concomitant with PARP inhibitors or carboplatin for treatment of ovarian cancer cell lines
30. Abstract 2723: Treatment of gastric cancer cells with tumor treating fields (TTFields) and concomitant FOLFOX
31. Abstract 2666: Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin or paclitaxel for treatment of cervical cancer
32. Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
33. Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959
34. Molecular Determinants of Allosteric Regulation in NCX Proteins
35. Lateral Gene Transfer and the Synthesis of Thymidine
36. Sodium recognition by the Na⁺/Ca²⁺ exchanger in the outward-facing conformation
37. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model
38. 860 In vivoeffectiveness of tumor treating fields (TTFields) concomitant with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC)
39. CSIG-41. SENSITIZING CANCER CELLS TO TUMOR TREATING FIELDS (TTFIELDS) BY INHIBITION OF PI3K
40. DNAR-10. THE EFFICACY OF TEMOZOLOMIDE AND LOMUSTINE IN GLIOBLASTOMA CELL LINES MAY BE ENHANCED BY CONCOMITANT TREATMENT WITH TUMOR TREATING FIELDS (TTFIELDS)
41. Heterozygous variants in the integrin subunit beta 4 gene (ITGB4) cause autosomal dominant nail dystrophy
42. Exploring the Li+ transporting mutant of NCX_Mj for assigning ion binding sites of mitochondrial NCLX
43. Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood–Brain Barrier In Vitro and In Vivo
44. Varicocoele in adolescence and testicular cancer in young adulthood
45. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields
46. 51587 Topical product compatibility with TTFields: Optimizing dermal adverse event management
47. Efficacy of combining tumor treating fields (TTFields) with a PARP inhibitor in ovarian cell lines (300.5)
48. Abstract 3465: Efficacy of concomitant application of Tumor Treating Fields (TTFields), temozolomide and lomustine in glioblastoma cancer cells in vitro
49. Abstract 1801: Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability
50. Abstract 2601: Concomitant treatment of ovarian cell lines with Tumor Treating Fields (TTFields) and PARP inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.